Egypt aims to produce 140 million vaccine doses annually by 2030

Egypt is accelerating efforts to enhance its pharmaceutical and biotechnology capabilities, with plans to produce 140 million human vaccine doses annually by 2030 under the new Vaccine City project. The initiative forms part of the country’s broader strategy to achieve self-sufficiency in vaccine production and expand exports to regional and international markets, reports Daily News Egypt, a partner of TV BRICS.

Khaled Abdel Ghaffar, the Egyptian Minister of Health and Population, reviewed the project’s progress, highlighting its strategic importance for strengthening national health security and localising advanced biotechnology industries. The development also includes the establishment of a specialised academy dedicated to training professionals in vaccine manufacturing and biotechnology, supporting the long-term sustainability of the sector.

Looking beyond 2030, Egypt aims to significantly scale up its production capacity, targeting 690 million human vaccine doses and 11 billion veterinary doses annually by 2040. This expansion is expected to enable the country to meet approximately 16 per cent of Africa’s vaccine demand, reinforcing its role in improving access to essential immunisations across the continent.

The project is also designed to position Egypt as a major export hub, with the potential to supply vaccines to more than 60 countries. In parallel, authorities are seeking to deepen cooperation with African nations and strengthen international partnerships in the biotechnology sector, fostering knowledge exchange.

Officials emphasise that the project represents a transformative step towards establishing an independent pharmaceutical manufacturing base. By enhancing domestic production capabilities and expanding regional collaboration, Egypt is positioning itself as a central player in Africa’s healthcare landscape while reinforcing the resilience of public health systems at both national and continental levels.